___

• 1. Shimosato Y, Kameya T, Nagai K, Suemasu K. Squa- mous cell carcinoma of the thymus. An analysis of eight cases. Am J Surg Pathol 1977;1(2):109–21.
• 2. Venuta F, Rendina EA, Longo F, De Giacomo T, Anile M, Mercadante E, et al. Long-term outcome after mul- timodality treatment for stage III thymic tumors. Ann Thorac Surg 2003;76(6):1866–72; discussion 1872.
• 3. Bretti S, Berruti A, Loddo C, Sperone P, Casadio C, Tessa M, et al; Piemonte Oncology Network. Multi- modal management of stages III-IVa malignant thy- moma. Lung Cancer 2004;44(1):69–77.
• 4. Kim ES, Putnam JB, Komaki R, Walsh GL, Ro JY, Shin HJ, et al. Phase II study of a multidisciplinary ap- proach with induction chemotherapy, followed by sur- gical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. Lung Cancer 2004;44(3):369–79.
• 5. Morio A, Nakahara K, Ohse Y, Tahara M, Goto T, Yaku- maru K et al. Efficacy of induction chemoradiotherapy in thymic cancer: report of a successful case and re- view of the literature. Int J Clin Oncol 2002;7:201–4.
• 6. Shintani Y, Ohta M, Hazama K, Miyoshi S, Kagisaki K and Matsuda H: Thymic carcinoma successfully re- sected with superior vena cava after chemoradiother- apy. Jpn J Thorac Cardiovasc Surg 2001;49:717–21.
• 7. Masaoka A, Monden Y, Nakahara K, Tanioka T. Fol- low-up study of thymomas with special reference to their clinical stages. Cancer 1981;48(11):2485–92.
• 8. Fornasiero A, Daniele O, Ghiotto C, Piazza M, Fiore-Donati L, Calabró F, et al. Chemotherapy for invasive thymoma. A 13-year experience. Cancer 1991;68(1):30–3.
• 9. Loehrer PJ Sr, Kim K, Aisner SC, Livingston R, Ein- horn LH, Johnson D, et al. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thy- moma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. J Clin Oncol 1994;12(6):1164–8.
• 10. Giaccone G, Ardizzoni A, Kirkpatrick A, Clerico M, Sahmoud T, van Zandwijk N. Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the Euro- pean Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 1996;14(3):814–20.
• 11. Highley MS, Underhill CR, Parnis FX, Karapetis C, Rankin E, Dussek J, et al. Treatment of invasive thy- moma with single-agent ifosfamide. J Clin Oncol 1999;17(9):2737–44.
• 12. Grassin F, Paleiron N, André M, Caliandro R, Bretel JJ, Terrier P, et al. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma. A French experi- ence. J Thorac Oncol 2010;5(6):893–7.
• 13. Loehrer PJ Sr, Jiroutek M, Aisner S, Aisner J, Green M, Thomas CR Jr, et al. Combined etoposide, ifos- famide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an inter- group trial. Cancer 2001;91(11):2010–5.
• 14. Albain KS, Swann RS, Rusch VW, Turrisi AT 3rd, Shep- herd FA, Smith C, et al. Radiotherapy plus chemo- therapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009;374(9687):379–86.
• 15. Hanna N, Neubauer M, Yiannoutsos C, McGarry R, Arseneau J, Ansari R, et al; Hoosier Oncology Group; US Oncology. Phase III study of cisplatin, etopo- side, and concurrent chest radiation with or without consolidation docetaxel in patients with inopera- ble stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 2008;26(35):5755–60.
• 16. Takada M, Fukuoka M, Kawahara M, Sugiura T, Yokoyama A, Yokota S, et al. Phase III study of con- current versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limit- ed-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 2002;20(14):3054–60.